84 results
8-K
EX-99.2
KA
Kineta Inc
12 Mar 24
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts
8:05am
changes in anti-tumor immune cell subpopulations Long-term stable disease observed in monotherapy and partial responses in combination therapy 2Q24
8-K
KA
Kineta Inc
12 Mar 24
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts
8:05am
a strategic transaction, it may be exposed to other operational and financial risks, including increased near-term or long-term expenditures, exposure … and financial risks, including:
oinability to retain key employees of the Company or any merged business;
oincreased near-term and long-term expenditures
8-K
EX-99.1
z8zj11 a2ps
24 May 23
Regulation FD Disclosure
9:30am
8-K
EX-99.6
jtf6r 9quali
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K
EX-99.2
0swaiyg en1gsxphdeq
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K
EX-99.5
xc8 sppnl
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K
EX-99.4
3y59thd3
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K
EX-10.6
ff47ut
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
424B3
hmad6b
10 Nov 22
Prospectus supplement
4:21pm